New data for Valneva and Pfizer's experimental vaccine for Lyme disease – the furthest ahead in clinical testing – have bolstered the case for the shot as the results of a phase 3 programme ...

Valneva has bolstered its vaccines pipeline with a shot designed to protect against shigellosis – a major global health threat – licensed from LimmaTech Biologics. The French pharma company ...

Valneva SE is a specialty vaccine company that develops, manufactures, and commercializes prophylactic vaccines for infectious diseases addressing unmet medical needs. It currently provides three ...

Great hopes rest on a product from the French-Austrian company Valneva. However, a vaccine from U.S. company Novavax, also based on proven technology, may reach more markets this winter.

The company has a market cap of $548.51 million, a PE ratio of -51.92 and a beta of 1.98. Valneva has a 12-month low of $3.62 and a 12-month high of $9.50. The company has a current ratio of 2.78 ...

If granted, IXCHIQ ® will become the first vaccine against the chikungunya virus (CHIKV) available in the EU for adolescents 12 years of age and older Saint Herblain (France), February 28, 2025 - ...